GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple myeloma. This pivotal trial demonstrated a statistically significant progression-free survival (PFS) benefit for Blenrep combined with bortezomib and dexamethasone (BorDex) against the daratumumab plus BorDex regimen.

Trial Details and Efficacy of Blenrep

The DREAMM-7 trial was unblinded early based on the recommendation of the Independent Data Monitoring Committee (IDMC). The primary endpoint of progression-free survival was met, indicating Blenrep’s effectiveness in prolonging the time to disease progression or death compared to the current standard of care. Notably, a strong overall survival trend with a nominal p value < 0.0005 was observed.

Comments from Hesham Abdullah, GSK’s Senior VP

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK, commented on the results, highlighting the need for efficacious treatments with novel mechanisms for multiple myeloma patients after the first relapse. Abdullah noted the encouraging potential of Blenrep combined with BorDex in addressing the high unmet need in this disease area.

Safety Profile and Upcoming Presentations

The safety and tolerability of the Blenrep regimen were consistent with the known profiles of the individual agents. The interim analysis results are set to be presented at an upcoming scientific meeting and shared with health authorities.

Ongoing DREAMM Clinical Development Programme

The DREAMM clinical development program continues to explore belantamab mafodotin’s potential in various treatment lines and combinations. This includes the ongoing phase III DREAMM-8 trial, with results expected in the second half of 2024.

  belantamab mafodotin, Blenrep, Blood Cancer, bortezomib, Daratumumab, Dexamethasone, DREAMM-7 trial, GSK, Hesham Abdullah, Multiple myeloma, Oncology